Singapore: Australia-based Allied Healthcare has marked a stronger sales with revenues up at 13 percent to $3.7 million for six months ending December 31, 2012, as compared to $3.319 million in the corresponding period of the previous year.

The company's overall loss attributed to members for the period was $2 million which includes costs associated with the increased activities around the regulatory filing for CardioCel and group's share of losses from investment company Coridon developing next generation vaccines to prevent and treat infectious diseases including cancers.

Over the past six months the company has continued to pursue regulatory marketing approval for CardioCel in major jurisdictions. CardioCel is group's leading regenerative tissue product and is used to treat and repair heart defects.

In the first half Allied has also reported positive data from pre-clinical studies for the Human Papilloma virus (HPV) therapeutic DNA vaccine. This program continues to progress through pre-clinical studies. Herpes Simplex virus (HSV-2) vaccine has also progressed well in its progress towards clinical studies with the phase I study well on track to be initiated in the second half of this financial year.